Zai Lab Ltd (ZLAB)

Zai Lab is a biopharmaceutical company headquartered in Shanghai with listings on NASDAQ (ZLAB), founded on the premise that high-quality drug discovery and development could be done outside the traditional centers of American and European biotech. The company searches for novel compounds and clinical treatments across oncology, autoimmune disease, and other therapeutic areas, bringing them through research, clinical trials, and regulatory approval, with the goal of commercializing them first in China and other Asian markets, and potentially in developed markets afterward. Zai Lab represents a particular moment in global biotech: the maturation of China’s research infrastructure, the rise of Chinese pharmaceutical talent returning from abroad, and the emergence of a large Chinese patient population that pharmaceutical companies increasingly want to serve.

The founding insight: quality biotech outside the West

Zai Lab was founded in 2014 by a team with deep connections to both Shanghai’s growing research universities and the global biotech industry. The founding insight was that China had the research talent, the infrastructure, and increasingly the patient population to support serious drug discovery, but that most global pharmaceutical companies were treating China primarily as a manufacturing base or as a market for drugs developed elsewhere. If a company could do original drug discovery in China — not copying Western drugs, but actually discovering new ones — it could capture value at the development stage rather than just at the manufacturing or sales stage.

This was a bold bet. Biotech drug development typically takes ten to fifteen years from initial research to market approval, costs hundreds of millions of dollars, and fails more often than it succeeds. It requires world-class research scientists, understanding of regulatory pathways, and the financial staying power to fund long clinical trials. These things were rare in China in 2014. Most Chinese biotech was still focused on generic drugs and on contract manufacturing for Western pharmaceutical companies. Zai Lab was positioning itself differently: as an original innovator, building a pipeline of novel compounds discovered through its own research or acquired from academic collaborators, and advancing those compounds through the clinical development system.

Drug discovery and the development pipeline

Zai Lab’s primary business is identifying and developing new drugs. The company works with academic research centers, hospitals, and biotech collaborators to identify promising compounds — molecules that show promise in the laboratory or in early research against cancer, inflammation, immunological disorders, and other diseases. When a promising compound is identified, Zai Lab acquires rights to it (often by licensing it from the researcher or institution that made the discovery) and then funds the expensive clinical development process.

Clinical development happens in phases. Phase I trials test safety in small groups of volunteers. Phase II trials test efficacy (does the drug actually work?) in a larger patient group. Phase III trials, the largest and most expensive, test whether the drug works better than the standard treatment or placebo in a large diverse population. Succeeding at each phase requires managing clinical sites, recruiting patients, monitoring safety, analyzing data, and reporting results to regulators. If a drug succeeds in Phase III, the company submits for regulatory approval (in China, through the National Medical Products Administration; in other countries through their analogues).

Zai Lab’s pipeline includes drugs in various stages of development. Some are in Phase I or II, where the main question is whether they are safe and show early signs of working. Others are further along, approaching the finish line of regulatory approval. The company’s goal is to advance multiple candidates through the pipeline simultaneously, accepting that most will fail, but that those that succeed will generate decades of revenue if the drug proves safe and effective.

Regulatory geography and the China advantage

A central feature of Zai Lab’s strategy is the geographic sequence of development. The company typically targets Chinese regulatory approval first, using China’s National Medical Products Administration as the primary path. This is economically sensible: China has enormous patient populations, and Chinese regulators are increasingly aligned with international standards. Gaining approval in China is typically faster and cheaper than running the massive multi-center Phase III trials required in the United States or Europe. Once a drug is approved in China and generating revenue, Zai Lab can decide whether to pursue approval in the United States or Europe — a more expensive proposition, but now one that is de-risked by Chinese approval and real-world use data.

This strategy also reflects a shift in global pharmaceutical economics. Historically, American and European drug companies developed drugs for wealthy markets first, then sometimes brought them to developing markets later. Zai Lab’s approach inverts that: develop for China first (a large, middle-income market with huge patient populations), then export globally. This is more capital-efficient for the company and reflects the reality that many diseases are very common in China; Chinese patients need effective treatments, and Chinese regulators are increasingly willing to approve drugs that meet international safety and efficacy standards.

The business model and cash flow

Zai Lab generates revenue from the drugs it brings to market and sells commercially. For most of its existence, the company has not been profitable: it has been in the investment phase, burning cash on research, clinical trials, and regulatory submissions. This is normal for biotech companies. The path to profitability only comes when approved drugs can be sold in sufficient volume to cover all the development costs and generate a profit.

The company also earns revenue through collaborations and partnerships with other pharmaceutical companies. A larger pharmaceutical company might license rights to develop one of Zai Lab’s compounds in a geographic region or for a specific indication, paying an upfront fee plus royalties on any future sales. These partnerships provide cash to fund the company’s own development efforts.

Venture capital, strategic investors, and public market equity have funded Zai Lab’s research and development. The NASDAQ listing in 2015 was a significant milestone, providing access to global capital markets and giving early investors and employees a way to monetize their stakes. Biotech companies typically remain unprofitable for years, so investor patience and access to capital are essential to survival.

Competition and market position

Zai Lab competes with global pharmaceutical companies, other Chinese biotech firms, and academic medical centers for the same clinical talent, the same promising compounds, and the same patients in clinical trials. The global pharmaceutical majors have vastly more resources, established regulatory relationships, and portfolios of approved drugs generating cash. Other Chinese biotech firms are pursuing similar strategies, sometimes with more capital or more established relationships.

Zai Lab’s advantages are its focus on Asian markets (especially China), its understanding of Chinese regulatory pathways and patient populations, and the technical talent it has attracted. Its disadvantages are its lack of a sales force or distribution infrastructure in developed markets, its shorter operating history compared to global companies, and the concentration of its risk in China and Asia. Geopolitical risk also looms: tensions between the United States and China affect trade, regulatory cooperation, and investor sentiment toward Chinese biotech.

What to watch

For investors researching Zai Lab, the most important thing is to understand the progress of its drug pipeline. Which candidates have succeeded in Phase II and are advancing to Phase III? Which are moving through Chinese regulatory approval? Have any drugs been approved and commercialized, and if so, what are the sales trends? The company’s 10-K filing (SEC CIK 0001704292) lays out the status of each major program and the timeline for key regulatory events.

Also watch the company’s cash position and cash burn rate. Biotech companies that are not yet profitable must be able to fund their operations through capital raises, partnerships, or a combination. A company that is burning cash faster than expected or that cannot access new capital is in danger. Conversely, a company that is reaching profitability from approved drugs has turned a corner. The earnings calls often discuss pipeline progress, regulatory timelines, and the company’s strategy for advancing candidates in different geographies. Understanding whether Zai Lab can successfully bring multiple drugs to market in China and expand into developed markets is the key question for the long-term investment case.